Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 29,534 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56. Following the sale, the insider owned 142,265 shares in the company, valued at approximately $10,931,642.60. This trade represents a 17.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total value of $709,808.26.

Liquidia Stock Performance

Shares of NASDAQ LQDA opened at $75.33 on Thursday. The stock’s 50-day moving average is $79.35 and its 200 day moving average is $55.93. The stock has a market cap of $6.74 billion, a price-to-earnings ratio of 54.99 and a beta of 0.58. Liquidia Corporation has a 1-year low of $21.15 and a 1-year high of $93.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm’s revenue was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.49) earnings per share. On average, sell-side analysts anticipate that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on LQDA shares. Stephens set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Royal Bank Of Canada set a $130.00 target price on Liquidia in a research note on Friday, July 24th. Lifesci Capital cut Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 target price for the company. in a report on Wednesday, August 12th. Finally, HC Wainwright set a $36.00 price target on Liquidia in a research note on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia presently has a consensus rating of “Hold” and a consensus price target of $98.08.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently modified their holdings of LQDA. Globeflex Capital L P bought a new stake in shares of Liquidia in the second quarter worth about $175,000. Bank of New York Mellon Corp bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $29,694,000. Handelsbanken Fonder AB bought a new stake in shares of Liquidia in the 2nd quarter worth approximately $1,993,000. Fulcrum Equity Management purchased a new position in shares of Liquidia during the second quarter valued at approximately $399,000. Finally, Fluent Financial LLC purchased a new position in shares of Liquidia during the second quarter valued at approximately $287,000. 64.54% of the stock is owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).